Dr. Jose Baselga from Massachusetts General Hospital Discusses the BOLERO Breast Cancer Trials
José Baselga, MD, PhD, a professor in the Department of Medicine at Harvard Medical School and chief of Hematology/Oncology at Massachusetts General Hospital, describes the 3 phase III BOLERO trials investigating everolimus (Afinitor), a mammalian target of rapamycin inhibitor, in various stages of breast cancer.
If the results from the BOLERO-1 and 3 trials are as positive as BOLERO-2 they will demonstrate the efficacy of everolimus in HER2-positive breast cancer, in both the first-line and refractory setting. BOLERO-2 was a second-line trial; Baselga feels a follow up study should include the first-line and adjuvant setting.
The findings of the BOLERO-2 trial go far beyond the patient population in the study. This research opens up the entire field of mTOR/PI3K-targeted therapies in multiple tumor types.